Road to 2025: DXB helping to treat kidney and respiratory disease

Stockheads

01-16

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.

Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials.

Tune in to find out what to look out for in 2025.

This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Explore More

Investor Guide: Health & Biotech FY2025 featuring Tim Boreham

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503607979"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503607979\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503607979?lang=zh_TW&edition=fundamental","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/DMX-1200x675-1-640x360.jpg","is_english":true,"pubTime":"2025-01-16 09:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503607979","market":"hk","top_or_hot":-1,"title":"Road to 2025: DXB helping to treat kidney and respiratory disease","media":"Stockheads","content":"<html><body><div><div></div></div><p>Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.</p><p><strong>Dimerix (ASX:DXB)</strong> is <span>working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials. </span></p><p>Tune in to find out what to look out for in 2025.</p><p><i>This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.</i></p><p><i>The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.</i></p><div></div><div> <h2>Explore More</h2> <ul><li> <img decoding=\"async\" height=\"169\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1.jpg 1200w\" width=\"300\"/> <span>Investor Guide: Health &amp; Biotech FY2025 featuring Tim Boreham</span> </li> </ul></div><div></div></body></html>","source":"stockheads_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Road to 2025: DXB helping to treat kidney and respiratory disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoad to 2025: DXB helping to treat kidney and respiratory disease\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Stockheads</strong><span class=\"h-time small\">2025-01-16 09:13</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div><div></div></div><p>Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.</p><p><strong>Dimerix (ASX:DXB)</strong> is <span>working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials. </span></p><p>Tune in to find out what to look out for in 2025.</p><p><i>This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.</i></p><p><i>The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.</i></p><div></div><div> <h2>Explore More</h2> <ul><li> <img decoding=\"async\" height=\"169\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1.jpg 1200w\" width=\"300\"/> <span>Investor Guide: Health &amp; Biotech FY2025 featuring Tim Boreham</span> </li> </ul></div><div></div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/\">Stockheads</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DXB","symbol_name":"Deutsche Bank Contingent Capital","start_time":0,"source_url":"https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/","article_id":"2503607979","we_media_id":null,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/DMX-1200x675-1-640x360.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503607979","pubTimestamp":1736989984,"columns":[],"sourceInfo":{"source_id":"stockheads_stock","name":"Stockheads"},"weMediaInfo":null,"summary":"Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix  is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis , a second licensing deal and regulatory and ethics approval for their clinical trials.Tune in to find out what to look out for in 2025.This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Explore More   Investor Guide: Health & Biotech FY2025 featuring Tim Boreham","collect":0,"end_time":0,"defaultTopTitle":"stockhead.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"DXB":"Deutsche Bank Contingent Capital","FSGS":"First Trust SMID Growth Strength ETF"},"translate_title":"2025年之路：DXB帮助治疗肾脏和呼吸系统疾病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB":1,"FSGS":1},"content_text":"Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials. Tune in to find out what to look out for in 2025.This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Explore More   Investor Guide: Health & Biotech FY2025 featuring Tim Boreham","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}